blfs-20251231

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-K/A

Amendment No. 1

(Mark One)

☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the year ended December 31, 2025

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-36362

BioLife Solutions, Inc.

(Exact name of registrant as specified in its charter)


Delaware			94-3076866
(State or other jurisdiction of incorporation or organization)			(IRS Employer Identification No.)

3303 Monte Villa Parkway, Suite 310, Bothell, Washington, 98021

(Address of registrant’s principal executive offices, Zip Code)

(425) 402-1400

(Telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol	Name of exchange on which registered
Common stock, par value $0.001 per share	BLFS	The Nasdaq Stock Market, LLC

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☑ No o

Indicate by check mark whether the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No ☑

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (S232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such said files). Yes ☑ No o


		Page No.
PART III

ITEM 10.	DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE	3
ITEM 11.	EXECUTIVE COMPENSATION	10
ITEM 12.	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS	33
ITEM 13.	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE	35
ITEM 14.	PRINCIPAL ACCOUNTING FEES AND SERVICES	36

PART IV

ITEM 15.	EXHIBITS AND FINANCIAL STATEMENT SCHEDULES	36
	SIGNATURES	40


Name						Position with the Company
Roderick de Greef						Chief Executive Officer and Chairman of the Board
Troy Wichterman						Chief Financial Officer
Aby J. Mathew						Chief Scientific Officer and Executive Vice President
Todd Berard						Chief Commercial Officer
Sean Werner						Chief Technology Officer


We Do						We Don’t
Pay for Performance: We emphasize market-based compensation that aligns the interests of our shareholders and executive officers through the use of both near-term cash incentive compensation and long-term equity awards subject to both time and market-based vesting.						Hedge or Pledge: We do not allow executive officers to engage in hedging or pledging of our securities.
Benchmark: We maintain an industry-specific peer group for annual benchmarking of executive compensation. This benchmarking is a key factor among those used to determine appropriate compensation for our NEOs.						Re-Pricing: We do not allow re-pricing of underwater stock options without shareholder approval.
Benefits: We offer market-competitive benefits for executives that are consistent with the benefits we offer all our employees.						Gross up Payments: We do not provide excise tax gross-up payments for our executive officers.
Consult: We consistently engage an independent compensation consultant to advise on compensation levels and practices.						Guaranteed Bonuses: We do not provide guaranteed bonuses to our executive officers.
Risk Assessment: We perform an annual compensation risk assessment.


Name	2025 Base Salary ($) (1)	2024 Base Salary ($) (1)	Base Salary Increase in 2025 vs 2024 (%)
Roderick de Greef	763,000	744,450	2
Troy Wichterman	505,000	472,000	7
Aby J. Mathew	460,000	435,000	6
Sean Werner	440,000	350,000	26
Todd Berard	443,000	370,000	20


Company Objective	Percentage of Executive Bonus Payout
Revenue target	30	%
Adjusted EBITDA margin target	30	%
Filing Annual Report with no material weaknesses target	20	%
NetSuite MRP module target	20	%
Total	100	%


	December 31,
	2025
GAAP Net loss from continuing operations	$	(12,130)
Total bonus excluded from Net loss for performance measure(1)	3,160
Net loss from continuing operations before bonus amounts	$	(8,970)

ADJUSTMENTS:
Interest (income) expense, net	(2,706)
Accretion of available-for-sale investments	(769)
Income tax expense	49
Depreciation	849
Intangible asset amortization	1,307
EBITDA	$	(10,240)

OTHER ADJUSTMENTS:
Share-based compensation (non-cash)	21,272
Acquisition and divestiture costs	1,904
Severance costs	732
IPR&D expense	15,521
Loss on disposal of assets	1
Other income	(1,046)
ADJUSTED EBITDA	$	28,144
% of Revenue	29		%


Name	Target Award as % of Salary for the Fiscal Year Ended December 31, 2025	Portion Tied to Company Objectives (%)
Roderick de Greef	100	100
Troy Wichterman	60	100
Aby J. Mathew	50	100
Sean Werner	50	100
Todd Berard	55	100


Company Objectives for the Fiscal Year Ended December 31, 2025
Revenue target			Revenues of $96 million met maximum payout of 39%
Adjusted EBITDA margin target			Adjusted EBITDA margin of 29% of total revenues met maximum payout of 39%
No material weaknesses in Annual Report			The Company successfully filed the 2025 Annual Report with no material weaknesses.
Implementation of NetSuite MRP module			The Company did not fully implement the NetSuite MRP module during 2025, resulting in 0% payout of this objective.


Name(1)	Target Award as % of Salary for the Fiscal Year Ended December 31, 2025	2025 Company Objectives Results (%)	2025 Bonus Payout ($)	2025 Overall Achievement % of Base Salary
Roderick de Greef	100	98	747,740	98
Troy Wichterman	60	98	296,940	59
Aby J. Mathew	50	98	225,400	49
Sean Werner	50	98	215,600	49
Todd Berard	55	98	238,777	54


Name	Service-vesting awards (#)	Target Market-based awards (#)
Roderick de Greef	112,835	112,835
Troy Wichterman	38,102	38,102
Aby J. Mathew	22,919	22,919
Sean Werner	22,919	22,919
Todd Berard	19,099	19,099


Name and Principal Positions (a)	Year (b)	Salary ($) (c)(1)		Bonus ($) (d)		Stock Awards ($) (e)(2)		Non-Equity Incentive Plan Compensation ($) (f)(3)		All Other Compensation ($) (g)		Total ($) (h)

Roderick de Greef	2025	763,000		—		8,890,551	(4)	747,740	(5)	68,066	(6)	10,469,357
Chief Executive Officer and	2024	744,450		—		5,571,874		655,116		74,765		7,046,205
Chairman of the Board	2023	198,890	(7)	62,740	(8)	4,588,883		—		466,285		5,316,798

Troy Wichterman	2025	505,000		—		2,456,055	(9)	296,940	(10)	14,000	(11)	3,271,995
Chief Financial Officer	2024	472,000		—		1,820,443		249,216		12,348		2,554,007
	2023	472,000		—		1,212,021		—		13,200		1,697,221

Aby J. Mathew	2025	460,000		—		2,487,763	(12)	225,400	(13)	14,000	(14)	3,187,163
Executive Vice President and	2024	435,000		—		1,111,511		172,260		14,723		1,733,494
Chief Scientific Officer	2023	435,000		—		897,488		—		13,200		1,345,688

Sean Werner - Chief Technology Officer	2025	440,000		—		1,477,359	(15)	215,600	(16)	14,000	(17)	2,146,959

Todd Berard	2025	443,000		—		1,231,122	(18)	238,777	(19)	14,000	(20)	1,926,899
Chief Commercial Officer	2024	336,373	(21)	—		630,860		148,004		12,258		1,127,495


			Estimated Future Payouts Under Non-Equity Incentive Plan Awards			Estimated Future Payouts Under Equity Incentive Plan Awards			All Other Stock Awards: Number of	Grant Date Fair Value of
Name (a)	Award Type	Grant Date (b)	Threshold ($) (c) (1)	Target ($) (d)	Maximum ($) (e)	Threshold (#) (c) (2)	Target (#) (d)	Maximum (#) (e)	Shares of Stock or Units (#) (e)	Stock Awards ($) (f) (3)

Roderick de Greef	Cash incentive	-	152,600	763,000	900,340	—	—	—	—	—
Roderick de Greef	Modified performance-based RSUs	3/18/2025				—	—	—	—	1,617,206
Roderick de Greef	Market-based RSUs	3/18/2025				28,209	112,835	225,670	—	4,415,234
Roderick de Greef	Service-vesting RSUs	3/18/2025				—	—	—	112,835	2,858,111
Troy Wichterman	Cash incentive	-	60,600	303,000	357,540	—	—	—	—	—
Troy Wichterman	Market-based RSUs	3/18/2025				9,526	38,102	76,204	—	1,490,931
Troy Wichterman	Service-vesting RSUs	3/18/2025				—	—	—	38,102	965,124
Aby J. Mathew	Cash incentive	-	46,000	230,000	271,400	—	—	—	—	—
Aby J. Mathew	Market-based RSUs	3/18/2025				5,730	22,919	45,838	—	896,820
Aby J. Mathew	Service-vesting RSUs	3/18/2025				—	—	—	22,919	580,538
Aby J. Mathew	Service-vesting RSUs	5/29/2025				—	—	—	45,269	1,010,404
Sean Werner	Cash incentive	-	44,000	220,000	259,600	—	—	—	—	—
Sean Werner	Market-based RSUs	3/18/2025				5,730	22,919	45,838	—	896,820
Sean Werner	Service-vesting RSUs	3/18/2025				—	—	—	22,919	580,538
Todd Berard	Cash incentive	-	48,730	243,650	287,507	—	—	—	—	—
Todd Berard	Market-based RSUs	3/18/2025				4,775	19,099	38,198	—	747,344
Todd Berard	Service-vesting RSUs	3/18/2025				—	—	—	19,099	483,778


	STOCK AWARDS
Name (a)	Grant Date (b)	Number of shares or units of stock that have not vested (#) (c)		Market value of shares or units of stock that have not vested (1) ($) (d)	Equity incentive plan awards: Number of unearned shares, units or other rights that have not vested (#) (e)		Equity incentive plan awards: Market or payout value of unearned shares, units or other rights that have not vested ($)(1)(f)
Roderick de Greef	10/19/2023	197,428	(2)	4,773,809	—		—
Roderick de Greef	3/8/2024	—		—	389,315	(3)	9,413,637
Roderick de Greef	3/18/2025	112,835	(4)	2,728,350	112,835	(5)	2,728,350

Troy Wichterman	2/24/2022	1,461	(6)	35,327	—		—
Troy Wichterman	1/3/2023	10,718	(7)	259,161	—		—
Troy Wichterman	3/8/2024	23,465	(8)	567,384	64,866	(9)	1,568,460
Troy Wichterman	3/18/2025	38,102	(10)	921,306	38,102	(11)	921,306

Aby J. Mathew	2/24/2022	1,315	(12)	31,797	—		—
Aby J. Mathew	1/3/2023	6,544	(13)	158,234	—		—
Aby J. Mathew	3/8/2024	14,327	(14)	346,427	39,605	(15)	957,649
Aby J. Mathew	3/18/2025	22,919	(16)	554,181	22,919	(17)	554,181
Aby J. Mathew	5/29/2025	45,269	(18)	1,094,604	—		—

Sean Werner	2/24/2022	366	(19)	8,850	—		—
Sean Werner	7/17/2024	10,312	(20)	249,344	—		—
Sean Werner	3/18/2025	22,919	(21)	554,181	22,919	(22)	554,181

Todd Berard	2/24/2022	877	(23)	21,206	—		—
Todd Berard	1/3/2023	3,715	(24)	89,829	—		—
Todd Berard	3/8/2024	8,132	(25)	196,632	22,479	(26)	543,542
Todd Berard	3/18/2025	19,099	(27)	461,814	19,099	(28)	461,814


	Stock Awards
Name (a)		Number of Shares Acquired on Vesting (#) (d)	Value Realized on Vesting ($) (e)(1)
Roderick de Greef		98,714	2,750,172
Troy Wichterman		93,038	2,291,734
Aby J. Mathew		58,586	1,443,832
Sean Werner		6,892	159,938
Todd Berard		33,823	833,804


	Payments and Benefits
Name	Base Salary ($)	Accelerated Vesting of Equity Awards ($) (1)	Health Insurance Under COBRA ($)	Total ($)
Roderick de Greef	763,000	19,644,146	43,268	20,450,414
Troy Wichterman	505,000	4,272,945	26,815	4,804,760
Aby J. Mathew	460,000	3,697,074	13,638	4,170,712
Sean Werner	220,000	1,366,557	15,023	1,601,580
Todd Berard	443,000	1,774,836	43,268	2,261,104


	Payments and Benefits
Name	2025 Target Annual Cash Incentive ($)	Accelerated Vesting of Equity Awards ($) (1)	Total ($)
Roderick de Greef	747,740	19,644,146	20,391,886
Troy Wichterman	296,940	4,272,945	4,569,885
Aby J. Mathew	225,400	3,697,074	3,922,474
Sean Werner	215,600	1,366,557	1,582,157
Todd Berard	238,777	1,774,836	2,013,613


Roderick de Greef (CEO) 2025 Compensation	$	10,469,357
Median Employee 2025 Compensation	$	125,725
CEO Pay Ratio	83:1


	Annual Retainer

Lead Director	$	40,000
Audit Committee Chair	$	20,000
Compensation Committee Chair	$	15,000
Governance and Nominating Committee Chair	$	10,000


Name	Annual Cash Retainer ($)	Board and Committee Chair Fees ($)	Total Cash Compensation ($)
Cathy Coste	70,000	20,000	90,000
Amy DuRoss	70,000	55,000	125,000
Rachel Ellingson	70,000	—	70,000
Joydeep Goswami	70,000	10,000	80,000
Tony Hunt	70,000	—	70,000
Tim Moore	70,000	—	70,000


Name	Fees Earned or Paid in Cash ($)	Stock Awards ($) (1)(2)	Total Compensation ($)
Cathy Coste	90,000	144,406	234,406
Amy DuRoss	125,000	174,169	299,169
Rachel Ellingson	70,000	174,169	244,169
Joydeep Goswami	80,000	174,169	254,169
Tony Hunt	70,000	174,169	244,169
Tim Moore	70,000	174,169	244,169


Name						Number of Unvested RSUs (#)
Cathy Coste						5,701
Amy DuRoss						6,876
Rachel Ellingson						6,876
Joydeep Goswami						6,876
Tony Hunt						6,876
Tim Moore						6,876


Name and Address of Beneficial Owner	Common Stock	Percentage of Class (1)
Directors and Executive Officers
Roderick de Greef (Officer and Director)(2)	340,014	*
Aby J. Mathew (Officer)(3)	293,974	*
Troy Wichterman(Officer)(4)	134,029	*
Todd Berard (Officer)(5)	121,987	*
Sean Werner (Officer)	48,251	*
Rachel Ellingson (Director)	49,825	*
Joydeep Goswami (Director)	44,986	*
Tim Moore (Director)	36,773	*
Amy DuRoss (Lead Director)	18,687	*
Tony Hunt (Director)	6,876	*
Cathy Coste (Director)	5,701	*
Total shares owned by Executive Officers and Directors (11 persons)	1,101,103	2.3	%
5% Stockholders
Casdin Capital, LLC (6)	5,957,165	12.2	%
BlackRock, Inc.(7)	5,424,116	11.1	%
T. Rowe Price Investment Management, Inc. (8)	5,180,824	10.6	%
Invesco LTD Inc. (9)	3,932,191	8.0	%
Vanguard Group, Inc. (10)	2,571,608	5.3	%


Plan category	Number of securities to be issued upon exercise of outstanding options or rights (in thousands)	Weighted Average exercise price of outstanding options or rights		Number of granted restricted stock awards outstanding (in thousands)	Number of securities remaining available for future issuance under equity compensation plans (in thousands)
Equity compensation plans approved by stockholders: Second amended and restated 2013 performance incentive plan	117	$	2.73	70	707
Equity compensation plans approved by stockholders: 2023 Omnibus performance incentive plan	—	$	—	1,731	1,492


	2025		2024

Audit fees(1)	$	1,996,490	$	2,418,450
Tax fees(2)	16,647		227,823
Total	$	2,013,137	$	2,646,273


Exhibit Number						Document
2.1†*						Agreement and Plan of Merger, dated as of March 19, 2021, by and among the Company, BLFS Merger Subsidiary, Inc., Global Cooling, Inc. and Albert Vierling and William Baumel, in their capacity as the representatives of the stockholders of Global Cooling, Inc. (included as Exhibit 2.1 to the current report on Form 8-K filed by the Company with the SEC on March 25, 2021)
2.2†						Agreement and Plan of Merger, dated as of August 9, 2021, by and among the Company, BLFS Merger Sub, Inc., Sexton Biotechnologies, Inc. and Fortis Advisors LLC, in their capacity as the representatives of the stockholders of Sexton Biotechnologies, Inc. (incorporated by reference to Exhibit 2.6 to Company's report on Form 10-K filed by the Company with the SEC on March 31, 2022)
2.3†*						Stock Purchase Agreement, dated April 17, 2024, by and between BioLife Solutions, Inc. and GCI Holdings Company, LLC (incorporated by reference to Exhibit 10.1 to the Company’s report on Form 8-K filed by the Company with the SEC on April 23, 2024)
2.4†*						Stock Purchase Agreement, dated November 12, 2024, by and between BioLife Solutions, Inc., SciSafe, Inc., and Subzero Purchaser Corp. (incorporated by reference to Exhibit 10.1 to the Company’s report on Form 8-K filed by the Company with the SEC on November 12, 2024)


2.5†*						Stock Purchase Agreement, dated November 14, 2024, by and between BioLife Solutions, Inc. and Standex International Corporation (incorporated by reference to Exhibit 10.1 to the Company’s report on Form 8-K filed by the Company with the SEC on November 20, 2024)
3.1						Amended and Restated Certificate of Incorporation of BioLife Solutions, Inc. (included as Exhibit 4.1 to the Registration Statement on Form S-8 filed by the Company with the SEC on June 24, 2013)
3.2						Certificate of Amendment to the Amended and Restated Certificate of Incorporation of BioLife Solutions, Inc. (included as Exhibit 3.1 to the Current Report on Form 8-K filed by the Company with the SEC on January 30, 2014)
3.3						Amended and Restated Bylaws of BioLife Solutions, Inc., effective November 12, 2024 (incorporated by reference to Exhibit 10.1 to the Company’s report on Form 8-K filed by the Company with the SEC on November 12, 2024)
3.4						Certificate of Designations, Preferences, and Rights of Series A Preferred Stock (included as Exhibit 3.1 to the current report on Form 8-K filed by the Company with the SEC on July 6, 2017)
4.1						Description of the Company’s Securities Registered under Section 12 of the Exchange Act (incorporated by reference to Exhibit 4.1 to the Company's Annual Report on Form 10-K filed by the Company with the SEC on February 26, 2026)
10.1**						BioLife Solutions, Inc. 2023 Omnibus Incentive Plan (included as Exhibit 4.1 to the Registration Statement on Form S-8 filed by the Company with the SEC on August 15, 2023)
10.2**						BioLife Solutions, Inc. Employee and Executive Form of Restricted Stock Unit Award Agreement pursuant to the 2023 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company’s report on Form 10-K filed by the Company with the SEC on February 29, 2024)
10.3**						BioLife Solutions, Inc. Director Form of Restricted Stock Unit Award Agreement pursuant to the 2023 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company’s report on Form 10-K filed by the Company with the SEC on February 29, 2024)
10.4**						Second Amended and Restated 2013 Performance Incentive Plan (included as Appendix A to the Registrant’s Definitive Proxy Statement filed by the Company with the SEC on April 14, 2017)
10.5**						Amendment No. 1 to Second Amended and Restated 2013 Performance Incentive Plan (included as Exhibit 10.2 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed by the Company with the SEC on March 31, 2021)
10.6**						BioLife Solutions, Inc. Form of Non-Plan Stock Option Agreement (included as Exhibit 4.4 to the Registration Statement on Form S-8 filed by the Company with the SEC on June 24, 2013)
10.7**						Form of Restricted Stock Purchase Agreement pursuant to the Second Amended & Restated 2013 Performance Incentive Plan (included as Exhibit 10.4 to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 filed by the Company with the SEC on May 16, 2016)
10.8**						Form of Stock Option Agreement pursuant to the Second Amended & Restated 2013 Performance Incentive Plan (included as Exhibit 10.5 to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 filed by the Company with the SEC on May 16, 2016)
10.9**						Amendment No. 2 to BioLife Solutions, Inc. Second Amended and Restated 2013 Performance Incentive Plan (incorporated by reference to Exhibit 4.5 of the Registrant’s Registration Statement on Form S-8 filed by the Company with the SEC on July 7, 2021)
10.10**						Amendment No. 3 to BioLife Solutions, Inc. Second Amended and Restated 2013 Performance Incentive Plan (incorporated by reference to Exhibit 4.6 of the Registrant's Registration Statement on Form S-8 filed by the Company with the SEC on September 12, 2022)
10.11						Twelfth Amendment to the Lease, dated June 5, 2024, by and between the Company and ARE-SEATTLE No. 38, LLC (included as Exhibit 10.11 to the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed by the Company with the SEC on March 3, 2025)
10.12						Lease Agreement dated October 1, 2019 for facility space 1102 Indiana Avenue, Indianapolis, IN 46202 (incorporated by reference to Exhibit 10.26 to the Company's report on Form 10-K filed by the Company with the SEC on March 31, 2022)
10.13						Second Amendment to the Lease, dated November 5, 2024 for facility space 1102 Indiana Avenue, Indianapolis, IN 46202 (included as Exhibit 10.13 to the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed by the Company with the SEC on March 3, 2025)
10.14						Lease Agreement dated September 13, 2022 for facility space 19510 144th Avenue NE, Suite A-1, Woodinville, WA 98072 (included as Exhibit 10.14 to the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed by the Company with the SEC on March 3, 2025)
10.15*						Loan and Security Agreement, dated September 20, 2022, between BioLife Solutions, Inc. and Silicon Valley Bank (incorporated by reference to Exhibit 10.1 to the Company's report on Form 10-Q filed by the Company with the SEC on November 9, 2022)


10.16*						Waiver and First Amendment to Loan and Security Agreement, dated February 26, 2024, between BioLife Solutions, Inc. and First Citizens Bank and Trust Company (incorporated by reference to Exhibit 10.21 to the Company's Annual Report on Form 10-K filed by the Company with the SEC on February 29, 2024)
10.17*						Consent and Second Amendment to Loan and Security Agreement, dated April 17, 2024, by and among Silicon Valley Bank, BioLife Solutions, Inc., SAVSU Technologies, Inc., Arctic Solutions, Inc., SciSafe Holdings, Inc., Global Cooling, Inc., and Sexton Biotechnologies, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s report on Form 8-K filed by the Company with the SEC on April 23, 2024)
10.18†						Consent and Third Amendment to Loan and Security Agreement, dated November 11, 2024, by and among Silicon Valley Bank, BioLife Solutions, Inc., SAVSU Technologies, Inc., Arctic Solutions, Inc., SciSafe Holdings, Inc., and Sexton Biotechnologies, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s report on Form 8-K filed by the Company with the SEC on November 12, 2024)
10.19†*						Consent and Fourth Amendment to Loan and Security Agreement, dated April 4, 2025, by and among Silicon Valley Bank, BioLife Solutions, Inc., SAVSU Technologies, Inc., and Sexton Biotechnologies, Inc. (incorporated by reference to Exhibit 10.19 to the Company's Annual Report on Form 10-K filed by the Company with the SEC on February 26, 2026)
10.20*						Consent and Fifth Amendment to Loan and Security Agreement, dated July 29 2025, by and among Silicon Valley Bank, BioLife Solutions, Inc., SAVSU Technologies, Inc., and Sexton Biotechnologies, Inc. (incorporated by reference to Exhibit 10.20 to the Company's Annual Report on Form 10-K filed by the Company with the SEC on February 26, 2026)
10.21†*						Consent and Sixth Amendment to Loan and Security Agreement, dated October 6 2025, by and among Silicon Valley Bank, BioLife Solutions, Inc., Sexton Biotechnologies, and PanTHERA (incorporated by reference to Exhibit 10.21 to the Company's Annual Report on Form 10-K filed by the Company with the SEC on February 26, 2026)
10.22**						Executive Employment Agreement, dated October 19, 2023, by and between the Company and Roderick de Greef (incorporated by reference to Exhibit 10.2 to the Company’s report on Form 8-K filed by the Company with the SEC on October 23, 2023)
10.23**						Amended Employment Agreement dated January 5, 2023 between the Company and Aby Mathew (included as Exhibit 10.21 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by the Company with the SEC on March 3, 2025)
10.24**						Amended Employment Agreement dated June 1, 2023 between the Company and Todd Berard (included as Exhibit 10.22 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by the Company with the SEC on March 3, 2025)
10.25**						Amended Employment Agreement dated June 1, 2023 between the Company and Karen Foster (included as Exhibit 10.23 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by the Company with the SEC on March 3, 2025)
10.26**						Amended Employment Agreement dated June 1, 2023 between the Company and Sarah Aebersold (included as Exhibit 10.24 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by the Company with the SEC on March 3, 2025)
10.27**						Amended Employment Agreement dated June 1, 2023 between the Company and Troy Wichterman (included as Exhibit 10.25 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by the Company with the SEC on March 3, 2025)
10.28**						Board of Directors Services Agreement entered into May 4, 2015 by and between the Company and Other Non-Employee Directors (included as Exhibit 10.3 to the Current Report on Form 8-K filed by the Company with the SEC on May 5, 2015)
10.29**						Form of Amendment to Employment Terms (incorporated by reference to Exhibit 10.1 to the Company’s report on Form 8-K filed by the C ompany with the SEC on August 16, 2023)
19.1						Insider Trading Policy (included as Exhibit 19.1 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by the Company with the SEC on March 3, 2025)
21.1						List of the Company’s Subsidiaries (incorporated by reference to Exhibit 21.1 to the Company's Annual Report on Form 10-K filed by the Company with the SEC on February 26, 2026)
23.1						Consent of Grant Thornton USA, LLP (incorporated by reference to Exhibit 23.1 to the Company's Annual Report on Form 10-K filed by the Company with the SEC on February 26, 2026)
31.1						Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (incorporated by reference to Exhibit 31.1 to the Company's Annual Report on Form 10-K filed by the Company with the SEC on February 26, 2026)
31.2						Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (incorporated by reference to Exhibit 31.2 to the Company's Annual Report on Form 10-K filed by the Company with the SEC on February 26, 2026)
31.3						Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)


31.4						Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
32.1						Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (incorporated by reference to Exhibit 32.1 to the Company's Annual Report on Form 10-K filed by the Company with the SEC on February 26, 2026)
32.2						Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (incorporated by reference to Exhibit 32.2 to the Company's Annual Report on Form 10-K filed by the Company with the SEC on February 26, 2026)
97.1						BioLife Solutions, Inc. Incentive-based compensation recovery policy (included as Exhibit 97.1 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by the Company with the SEC on March 3, 2025)
101.INS						Inline XBRL Instance Document (filed herewith)
101.SCH						Inline XBRL Taxonomy Extension Schema (filed herewith)
101.CAL						Inline XBRL Taxonomy Extension Calculation Linkbase (filed herewith)
101.DEF						Inline XBRL Taxonomy Extension Definition Linkbase (filed herewith)
101.LAB						Inline XBRL Taxonomy Extension Label Linkbase (filed herewith)
101.PRE						Inline XBRL Taxonomy Extension Presentation Linkbase (filed herewith)
104						Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)


*			Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10) or Item 601(b)(2) of Regulation S-K. An unredacted copy of this exhibit will be furnished supplementally to the Securities and Exchange Commission upon request.
**			Management contract or compensatory plan or arrangement.
†			Certain exhibits and schedules to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant agrees to provide a copy of any omitted exhibit or schedule to the Securities and Exchange Commission or its staff upon request.


Date:	April 28, 2026	BIOLIFE SOLUTIONS, INC.

		/s/ RODERICK DE GREEF
		Roderick de Greef
		Chief Executive Officer (principal executive officer) and Chairman of the Board of Directors

Amendment: SEC Form 10-K/A filed by BioLife Solutions Inc.